India Thalassemia Market Research Report Information by Type (Alpha-thalassemia and Beta-thalassemia) and by Treatment & Diagnosis (Treatment [Blood Transfusions, Drugs, Folic Acid Supplements] and Diagnosis [Instruments and Reagents) - Forecast till 2032

India Thalassemia Market Overview

India thalassemia market size was valued at USD 0.20 billion in 2022. The India thalassemia market industry is projected to grow from USD 0.21 billion in 2023 to USD 0.38 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.03% during the forecast period (2023 - 2032).

Growing government initiatives and support to raise awareness for thalassemia and increased prevalence of thalassemia in India are fueling the growth of the India thalassemia market.

 Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

India Thalassemia Market Trends

• Growing government initiatives and support to raise awareness for thalassemia

In recent years, the Indian government has taken significant steps towards raising awareness for thalassemia, a genetic blood disorder that affects a large number of people in the country. Government initiatives have played a crucial role in educating the public about thalassemia and its prevention methods. The Ministry of Health and Family Welfare has been actively involved in implementing various programs and campaigns to increase knowledge and understanding of this condition. For instance, in May 2023, Ministry of Health and Family Welfare (India) reported that Dr Bharati Pravin Pawar launched Phase-III of Thalassemia Bal Sewa Yojana. Furthermore, it also stated that combating blood disorders like Thalassemia requires a multi-pronged approach: ramping up screening efforts, bolstering awareness and counseling programs, and significantly expanding access to treatment facilities. These initiatives include organizing awareness camps, conducting medical screenings, and providing essential information about the disease to communities.

Moreover, the increased prevalence of thalassemia has indeed led to a higher demand for iron chelation therapy and folic acid supplements. Iron chelation therapy is essential in thalassemia patients to remove excess iron from the body and prevent complications such as organ damage, particularly in the heart and liver. The demand for iron chelators like deferasirox, deferiprone, and deferoxamine has increased with the rising prevalence of thalassemia cases. For instance, in August 2020, according to the Ministry of Health and Family Welfare in India, the country has the highest prevalence of thalassemia globally, with approximately 150,000 individuals affected, and an estimated 10,000 to 15,000 children born with the condition annually. Furthermore, supplementing with folic acid helps to support red blood cell production and can alleviate some of the symptoms of anemia associated with thalassemia.

Thus, the increasing government initiatives are creating huge awareness of thalassemia among Indian population and rising incidences of thalassemia in India are burgeoning the growth of India thalassemia.

India Thalassemia Market Segment Insights

India Thalassemia Type Insights

Based on type, the India thalassemia market is segmented into alpha-thalassemia and beta-thalassemia. Beta-thalassemia held the largest market share in 2022 and is anticipated to register the highest CAGR from 2022 to 2032. This is due to the factors such as rising prevalence of beta-thalassemia major (About 10,000 -15,000 babies with thalassemia major are born every year), growing emphasis on newborn screening programs for early identification and intervention, and increasing collaborations between pharmaceutical companies and research institutions.

India Thalassemia Treatment & Diagnosis Insights

Based on treatment & diagnosis, the India thalassemia market has been segmented into treatment and diagnosis. The treatment segment further divided into blood transfusions, drugs, and folic acid supplements immunoassay and diagnosis is bifurcated into instruments and reagents. Treatment held the largest market share in 2022 and diagnosis is anticipated to register the highest CAGR from 2022 to 2032. This growth is reflected due to some major factors such as rising prevalence of transfusion-dependent thalassemia patients, technological advancements in hemoglobinopathy testing, and advancements in genetic testing.

FIGURE 2: INDIA THALASSEMIA MARKET, BY TREATMENT & DIAGNOSIS, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

India Thalassemia Key Market Players & Competitive Insights

The India thalassemia market is distinguished by the presence of numerous local players catering to thalassemia products that are evolving at a rapid pace. Furthermore, the rising prevalence of type 2 diabetes, increased prevalence of thalassemia, and sickle cell disease coupled with growing awareness among Indians is further driving the growth of India thalassemia market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products, services and signing contracts and agreements to broaden their reach and reduce operational costs.

Furthermore, Agios Pharmaceuticals Inc. (US) discovers and creates novel medications to treat rare genetic metabolic disorders and cancer. AG-946, a novel PKR activator for the treatment of sickle cell disease and hemolytic anemias, is one of its pipeline products. The drug candidate mitapivat is also part of the company's pipeline; it is intended to treat adult sickle cell disease, adult thalassemia, adult pyruvate kinase (PK) deficiency, adult thalassemia, and pediatric sickle cell disease. Adults with PK deficiency can treat their hemolytic anemia with tablets from Agios under the Pyrukynd brand. The business provides the myAgios patient support services program, which consists of financial aid, prescription fulfillment, access support, illness education, and connections to the community. The company's strategic collaborations and financial strength position it well for continued growth and success in the biopharmaceutical industry. Furthermore, the company distributes its products through online channel across the world including India. Additionally, the company the U.S. Food and Drug Administration (FDA) has approved PYRUKYND (mitapivat) for the treatment of adults with pyruvate kinase (PK) deficiency, a rare, lifelong hemolytic anemia that is crippling. The product is available in India.

Key Companies in the India Thalassemia Market includes.

• Novartis AG (Switzerland)


• Cipla, Inc. (India)


• Sun Pharmaceutical Industries Ltd. (India)


• Bristol-Myers Squibb (US)


• Agios Pharmaceuticals, Inc. (US)


• Centurion Remedies Private Limited. (India)


• Healing Pharma India Pvt. Ltd. (India)


• Rewine Pharmaceuticals (India)


• Cadila Pharmaceuticals (India)


• Trexgen Pharmaceuticals Pvt Ltd. (India)

India Thalassemia Market Industry Developments

February 2022: The U.S. Food and Drug Administration (FDA) has approved PYRUKYND (mitapivat) for the treatment of adults with pyruvate kinase (PK) deficiency, a rare, lifelong hemolytic anemia that is crippling. The product is available in India.

India Thalassemia Market Segmentation

India Thalassemia Type Outlook

• Alpha-thalassemia


• Beta-thalassemia

India Thalassemia Treatment & Diagnosis Outlook

• Treatment
  
  
  
  • Blood Transfusions
  
  
  • Drugs
  
  
  • Folic Acid Supplements
  
  
  
  


• Diagnosis
  
  
  
  • Instruments
  
  
  • Reagents